Fridge-free vaccines inspired by resurrecting plant could save millions of wasted doses annually

Millions of vaccine doses are lost every year because they can’t survive the journey from factory to patient. Now researchers in the U.K. are testing a radically different approach: turning traditional liquid vaccines into a powder that can be stored and moved without constant refrigeration.

Inspired by hardy “resurrection plants” that can dry out for months and then revive with rain, the new technique could reduce waste, ease distribution in hot climates, and make immunizations more dependable for low- and middle-income countries.

From desert plants to pharmacy shelves: the science behind fridge-free vaccines

Certain plants surviving prolonged droughts produce a natural sugar called trehalose, which protects their cells while they’re dry. Scientists adapted that survival trick to stabilize a tetanus-diphtheria vaccine in powdered form. Instead of relying on constant cooling, the vaccine remains dormant until water is added, at which point it can be administered like a standard shot.

The powdered formulation was developed by a team including the U.K. National Institute for Health and Care Research (NIHR) and industry partner Stablepharma, aiming to translate the plants’ biochemical defense into a practical medical product.

How the powder performed in safety and stability tests

Real-world temperature stresses

In laboratory evaluations the trehalose-stabilized powder stayed viable at room temperature for up to a year. It also withstood extreme temperature swings intended to mimic actual transport conditions — for example moving from an aircraft cargo hold to ground transport — experiencing cycles between about -4°F and 104°F (-20°C to 40°C) without losing effectiveness.

Human testing and early immune responses

A small clinical assessment involving 60 volunteers showed the powder vaccine is safe and well-tolerated. Immune response measurements after reconstitution were in line with responses produced by conventional, temperature-controlled vaccines, suggesting the powder approach didn’t compromise protection.

Why removing cold-chain dependence could change global vaccine access

Maintaining a continuous, temperature-controlled supply chain — the “cold chain” — is expensive and fragile. Interruptions mean batches must be discarded. This problem is less visible in wealthier nations, but in many rural or tropical settings, inconsistent refrigeration and unreliable power can turn vaccine delivery into a race against heat.

• Lower wastage: Powdered vaccines that don’t require refrigeration could dramatically cut the number of doses thrown away.
• Easier logistics: Transporting light, stable powder reduces reliance on refrigerated trucks, ice packs, and constant monitoring devices.
• Improved reach: Clinics without dependable electricity could store and use vaccines safely, widening access in remote areas.

What’s next: trials, approvals, and limits of the method

Researchers plan a larger trial of about 160 participants in the near term to build on the initial safety and immunogenicity findings. Because the tetanus-diphtheria vaccine used in these tests is already licensed for human use, the pathway to commercialization could be shorter than for entirely new vaccines.

Still, the approach won’t work for every product. According to reporting from the BBC, advanced mRNA vaccines — like some COVID-19 shots — are unsuitable for this type of drying and reconstitution. However, many conventional vaccines and some biologic medicines, including certain monoclonal antibodies that currently require refrigeration, may be good candidates.

Opportunities and challenges for scaling powder vaccine technology

• Manufacturing adaptation: Facilities will need to adopt drying processes and quality controls to produce stable powders at scale.
• Regulatory hurdles: Even when the active ingredient is approved, regulators must evaluate the powdered formulation, packaging, and stability claims.
• Cost considerations: While storage and transport costs could drop, initial investment in new production lines and validation work will be required.

Experts involved say the promise is significant: a powder that preserves potency without refrigeration could reduce the frequency of wasted doses, simplify distribution networks, and make lifesaving vaccines reachable in places where cold storage is scarce.

You might also like:

• mRNA vaccine for allergies could eliminate hay fever and food allergies
• Cancer vaccine reduces melanoma risk 49% after five years
• Tuberculosis DNA vaccine nasal delivery shows therapeutic promise in Johns Hopkins study
• Flu deaths in children hit record highs this season
• Spray-on powder instantly seals life-threatening wounds in battle and disasters

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.